Average Co-Inventor Count = 5.14
ph-index = 6
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Rigel Pharmaceuticals, Incorporated (17 from 488 patents)
2. Five Prime Therapeutics, Inc. (9 from 71 patents)
3. Bristol-myers Squibb Compnay (5 from 3,681 patents)
4. Eureka Therapeutics, Inc. (1 from 48 patents)
27 patents:
1. 11827628 - Compositions and methods for inhibition of the JAK pathway
2. 11566076 - Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers
3. 11559583 - Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer
4. 11421034 - Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer
5. 11198689 - Compositions and methods for inhibition of the JAK pathway
6. 11155615 - Anti-ROR1 antibodies
7. 10982001 - Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
8. 10822421 - Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
9. 10618967 - Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
10. 10421752 - Compositions and methods for inhibition of the JAK pathway
11. 10221244 - Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
12. 10221243 - Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
13. 9765147 - Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
14. 9732073 - Compositions and methods for inhibition of the JAK pathway
15. 9248190 - Compositions and methods for inhibition of the JAK pathway